Device Trial Radar · NCT05492383
SAvvyWire™ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI)
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Oct 25, 2022
Primary completion
Mar 3, 2023
Study completion Mar 3, 2023
Sponsor
- Lead sponsor
- Opsens, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 8, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the clinical investigation is to determine efficacy and safety of using the rapid pacing of SavvyWire™ during TAVI procedures.
Conditions
- Severe Aortic Stenosis
Interventions
TAVIDevice
Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with effective rapid pacing runTime frame: during surgery
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.